Last reviewed · How we verify
NCT04709731: CarPAs
Cardiovascular Assessment of Ponatinib as Third Line Treatment in Chronic Phase Chronic Myeloid Leukemia
Phase 2 trial testing Ponatinib 15mg QD in Chronic Myeloid Leukemia (CML) in 50 participants. Status unknown.
31 October 2024
Quick facts
| Lead sponsor | Associazione Italiana Pazienti Leucemia Mieloide Cronica |
|---|---|
| Phase | Phase 2 |
| Status | Status unknown |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 50 |
| Start date | 1 February 2021 |
| Primary completion | 31 October 2024 |
| Estimated completion | 1 April 2025 |
| Sites | 13 locations across Italy |
Drugs / interventions tested
- Ponatinib 15mg QD — full drug profile →
- Ponatinib 30mg QD — full drug profile →
Conditions studied
- Chronic Myeloid Leukemia (CML) — all drugs for Chronic Myeloid Leukemia (CML) →
Sponsor
Associazione Italiana Pazienti Leucemia Mieloide Cronica — full company profile →
Who can join
Adults 18 to 99, any sex, with Chronic Myeloid Leukemia (CML). Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This study will address the therapeutic activity and the safety/biological profile of Ponatinib when used as third line therapy of Chronic Myeloid Leukemia in Chronic Phase after the only two TKIs known for their cardiovascular safety, i.e. Imatinib and Bosutinib.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT04709731
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Chronic Myeloid Leukemia (CML)
Currently open trials in the same condition.
- NCT07165535 — Quality of Life and Care Organization of Patients With Chronic Myeloid Leukemia in the Lombardy Hematology Network · recruiting
- NCT06514534 — Open-label Study of Asciminib for CML-CP or CML-AP Patients With T315I Mutation Who Are Resistant, Intolerant or Ineligi · Phase 2 · recruiting
- NCT05589896 — A First-in-Human Study of HLA-Partially to Fully Matched Allogenic Cryopreserved Deceased Donor Bone Marrow Transplantat · Phase 1, PHASE2 · recruiting
- NCT03849651 — TCRαβ-depleted Progenitor Cell Graft With Additional Memory T-cell DLI, Plus Selected Use of Blinatumomab, in Naive T-ce · Phase 2 · active not recruiting
- NCT03481868 — EPIgenetics and in Vivo Resistance of Chronic Myeloid Leukemia Stem Cells to Tyrosine Kinase Inhibitors · NA · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04709731 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Associazione Italiana Pazienti Leucemia Mieloide Cronica
- Last refreshed: 3 February 2021
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04709731.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing